Hasten is an innovation-driven pharmaceutical company building a commercial platform and a late-stage development pipeline of innovative assets. The company has pursued inorganic growth, including acquiring Chinese‑mainland exclusive rights for five cardiovascular and metabolism drugs from Takeda in March 2022. Management says proceeds from fundraising will be used to fund future acquisitions and business development of pipeline assets and to create a broader health management ecosystem in China. Hasten reported 47% growth in sales from Q2 to Q4 in 2022, which CBC cited as evidence of operational and growth momentum. The company is backed by CBC, Hefei Industry Investment Group, and Feidong County of Hefei City, and management aims to become a leading healthcare company serving chronic, age‑related, acute and severe disease patients.

Total raised

$315M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2023